- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
ASCO Picks Top Advances in Cancer Treatment
Advances in screening and prevention, treatments for refractory cancers, and ways to reduce cancer recurrence were part and parcel of the progress made against the disease in 2011, according to the American Society of Clinical Oncology.
A reduction in lung cancer death rates of 20% for high-risk individuals following low-dose computed tomography scanning was one of the more important screening advances of the past year. This was the first successful trial over many decades of trying to find a screening regimen for these patients, reported Steven I. Benowitz, MA, from ASCO, and colleagues.
Among the advances in new drug approvals was the clearance of crizotinib (Xalkori) for use in lung cancer patients whose tumor has a specific alteration in the anaplastic lymphoma kinase gene, the authors noted online in the Journal of Clinical Oncology. The 31% improved survival over two years was heralded as another example of successfully personalizing the treatment of cancers.
Source: Medpage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
